These data are out from real-time ad trackers at iSpot.tv and shared with Fierce Pharma Marketing. The company tracks pharma brand (not OTC) spending and is crunched from national TV ads from Jan. 1 to Dec. 31, 2023.

AbbVie took the top two TV drug ad spending spots with its immunology duo Rinvoq and Skyrizi, respectively, in December as it looks to cement its place as the pharma with the deepest direct-to-consumer pockets.

Check out the top 10 below, as compiled by real-time TV ad trackers iSpot.TV for Fierce Pharma Marketing.

The Illinois-based pharma giant claimed the top spot with its IL-23 immunology blockbuster drug Skyrizi, though the company's spending on this medicine was markedly down by $11 million month-over-month. AbbVie forked over $36.6 million for its Skyrizi ad last month, compared to $46.6 million in October.

According to the latest data from real-time TV ad tracker iSpot.TV for October, Skyrizi once again claimed the top spot, with spending skyrocketing from just over $30 million in September to $45.6 million last month.

According to the latest report from TV ad trackers at iSpot.TV, AbbVie spent $30.4 million in September on advertisements for its IL-23 immunology therapy Skyrizi, securing the top spot on the ad spenders' list. That's a $3.9 million increase from August, when AbbVie was also the top ad spender.

In particular, Ozempic stands out by allocating 41% of its advertising budget to online video platforms, such as streaming services, which represents a remarkable year-on-year increase of over 1,000%. Conversely, as evidenced by iSpot.TV's monthly TV drug advertising data, its investment in television advertising has experienced a contrasting decline of 23% compared to the previous year.

AbbVie has secured all three top positions among iSpot.tv's leading drug ad spenders in August, featuring two familiar contenders and one unexpected player. Meanwhile, several newcomers have surged into the top 10, while a prominent name has slipped down the rankings.

That’s according to a new report shared with Fierce Pharma Marketing by real-time ad tracker iSpot.TV. The report, which covered ad impressions for the first half of this year, found that pharma brands dominated the top 10 new brands with the highest ad impressions for TV airtime. In fact, pharma brands occupied five out of those spots including the top three positions.

After a big spending push during Mental Health Awareness Month in May, Otsuka and Lundbeck’s bipolar and schizophrenia drug Rexulti fell four places to ninth in June as it eased off the spending tap, while Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance rounded out the top 10.

Alkermes spent big in May for its schizophrenia and bipolar drug Lybalvi’s new TV spot as it looked to dovetail its messaging with Mental Health Awareness Month and switch up its initial soft launch into a hard commercial run.

Total spend for the top 10 in May hit $203.1 million, a big jump on the $177.3 million spent during April, as pharmas appear to be digging a little deeper into their ad spend budgets.

Check out the top 10, as complied for Fierce Pharma Marketing by real-time ad trackers at iSpot, below.

Overall spend across the top 10 was $177.3 million for April, almost exactly the same as March’s total at $177.1 million. Both figures are up from February’s lowly $151.6 million but massively down on the $207.4 million we saw in January.

Check out the top 10 from real-time ad trackers at iSpot.TV below.

While Novo Nordisk’s diabetes drug Ozempic was the talk of the town, it was Pfizer that spent the most on TV drug ads at this year’s Oscars.

That’s according to new data out from real-time trackers at iSpot.TV, which estimates that the Big Pharma spent $5.7 million on its new COVID-19 drug ad: “If it’s COVID, it’s Paxlovid” during a single Oscars airing on Sunday, March 12.

AbbVie’s immunology drug Skyrizi took the number one spot in February, according to data from real-time ad trackers at iSpot.TV, with the pharma shelling out $25.6 million on all TV drug ads for Skyrizi last month. That is down by nearly $12 million from January and foreshadows a drop in spending across the board.

While the Super Bowl this week is not a big draw for pharma, the Grammys provides a better opportunity to promote its products, and there were eight names all vying for your attention this year, according to data by real-time ad trackers at iSpot.TV and shared with Fierce Pharma Marketing.

After being crowned not just December’s biggest TV drug ad spender but also being No. 1 throughout last year, AbbVie’s Rinvoq started 2023 in its now accustomed top spot.

AbbVie’s JAK inhibitor topped the charts last month with an impressive $41.3 million in spend for its TV ads in January, up on the $40.6 million in December. That’s according to data shared with Fierce Pharma Marketing by real-time ad tracker iSpot.TV.

When it comes to prescription brands, pharma TV ad spending grew 8% in 2022, reaching a total of $4.05 billion. Some of that growth was fueled by large increases in ad spend for specific categories of drugs, according to Tyler Bobin, senior brand analyst at real-time ad tracker iSpot.TV. For example, national TV ad spend for the psoriasis, skin and nail industry jumped a whopping 46% from one year ago.

While the podium places are all familiar faces, we have a new contender in the form of Pfizer’s COVID vaccine Comirnaty, coming in fourth for September and its first-ever appearance in iSpot’s top 10.

Pfizer has been using a softly, softly approach when it comes to promoting its COVID-19 vaccine Comirnaty. But as the NFL season kicked off this month, the Big Pharma’s marketing strategy is going the extra yard.

That’s according to data and analysis shared with Fierce Pharma Marketing by real-time ad tracker iSpot.tv. These data find that since Aug. 22, ads for Comirnaty have aired 749 times on national linear TV, with a particular emphasis on NFL games, which started Sept. 9.

AbbVie has taken the top two spots in August’s TV drug ad spenders’ list as it pushes down fierce rival Dupixent into third place, according to real-time ad trackers at iSpot.

The Big Pharma’s immunology JAK inhibitor Rinvoq keeps the lead for a second month in a row, with a mighty $33.3 million spend in August. Though this was down on the near $40 million it spent in July, the amount doled out each of these last two months still marks the largest for any drug ad campaign over a month so far this year.